155 related articles for article (PubMed ID: 20631307)
1. Invariant NKT cells are required for antitumor responses induced by host-versus-graft responses.
Saito TI; Li HW; Sykes M
J Immunol; 2010 Aug; 185(4):2099-105. PubMed ID: 20631307
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of the antitumor responses and host-versus-graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: a critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-gamma-producing CD8+ T cells.
Rubio MT; Saito TI; Kattleman K; Zhao G; Buchli J; Sykes M
J Immunol; 2005 Jul; 175(2):665-76. PubMed ID: 16002661
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma.
Rubio MT; Kim YM; Sachs T; Mapara M; Zhao G; Sykes M
Blood; 2003 Sep; 102(6):2300-7. PubMed ID: 12791660
[TBL] [Abstract][Full Text] [Related]
4. Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice.
Willems L; Fevery S; Sprangers B; Rutgeerts O; Lenaerts C; Ibrahimi A; Gijsbers R; Van Gool S; Waer M; Billiau AD
Cancer Immunol Immunother; 2013 Nov; 62(11):1733-44. PubMed ID: 24081484
[TBL] [Abstract][Full Text] [Related]
5. Role of indirect allo- and autoreactivity in anti-tumor responses induced by recipient leukocyte infusions (RLI) in mixed chimeras prepared with nonmyeloablative conditioning.
Rubio MT; Zhao G; Buchli J; Chittenden M; Sykes M
Clin Immunol; 2006 Jul; 120(1):33-44. PubMed ID: 16675304
[TBL] [Abstract][Full Text] [Related]
6. Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras.
Dierckx de Casterlé I; Fevery S; Rutgeerts O; Poosti F; Struyf S; Lenaerts C; Waer M; Billiau AD; Sprangers B
Cancer Immunol Immunother; 2018 Apr; 67(4):589-603. PubMed ID: 29299660
[TBL] [Abstract][Full Text] [Related]
7. Recipient lymphocyte infusion in MHC-matched bone marrow chimeras induces a limited lymphohematopoietic host-versus-graft reactivity but a significant antileukemic effect mediated by CD8+ T cells and natural killer cells.
De Somer L; Sprangers B; Fevery S; Rutgeerts O; Lenaerts C; Boon L; Waer M; Billiau AD
Haematologica; 2011 Mar; 96(3):424-31. PubMed ID: 21109687
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
9. Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants.
Hongo D; Tang X; Dutt S; Nador RG; Strober S
Blood; 2012 Feb; 119(6):1581-9. PubMed ID: 22174155
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning.
Kim YM; Mapara MY; Down JD; Johnson KW; Boisgerault F; Akiyama Y; Benichou G; Pelot M; Zhao G; Sykes M
Blood; 2004 Jan; 103(2):732-9. PubMed ID: 14512313
[TBL] [Abstract][Full Text] [Related]
11. DC therapy induces long-term NK reactivity to tumors via host DC.
Shimizu K; Fujii S
Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
[TBL] [Abstract][Full Text] [Related]
12. Tolerogenic interactions between CD8
Hongo D; Tang X; Zhang X; Engleman EG; Strober S
Blood; 2017 Mar; 129(12):1718-1728. PubMed ID: 28096089
[TBL] [Abstract][Full Text] [Related]
13. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation.
Pillai AB; George TI; Dutt S; Teo P; Strober S
J Immunol; 2007 May; 178(10):6242-51. PubMed ID: 17475852
[TBL] [Abstract][Full Text] [Related]
14. Invariant NKT cells preferentially modulate the function of CD8 alpha+ dendritic cell subset in inducing type 1 immunity against infection.
Joyee AG; Uzonna J; Yang X
J Immunol; 2010 Feb; 184(4):2095-106. PubMed ID: 20089704
[TBL] [Abstract][Full Text] [Related]
15. Donor bone marrow cells are essential for iNKT cell-mediated Foxp3+ Treg cell expansion in a murine model of transplantation tolerance.
Miyairi S; Hirai T; Ishii R; Okumi M; Nunoda S; Yamazaki K; Ishii Y; Tanabe K
Eur J Immunol; 2017 Apr; 47(4):734-742. PubMed ID: 28127757
[TBL] [Abstract][Full Text] [Related]
16. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
Mattarollo SR; West AC; Steegh K; Duret H; Paget C; Martin B; Matthews GM; Shortt J; Chesi M; Bergsagel PL; Bots M; Zuber J; Lowe SW; Johnstone RW; Smyth MJ
Blood; 2012 Oct; 120(15):3019-29. PubMed ID: 22932803
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease.
Zeng D; Lewis D; Dejbakhsh-Jones S; Lan F; García-Ojeda M; Sibley R; Strober S
J Exp Med; 1999 Apr; 189(7):1073-81. PubMed ID: 10190898
[TBL] [Abstract][Full Text] [Related]
18. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
[TBL] [Abstract][Full Text] [Related]
19. Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4.
Kim JH; Choi EY; Chung DH
J Immunol; 2007 Nov; 179(10):6579-87. PubMed ID: 17982047
[TBL] [Abstract][Full Text] [Related]
20. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction.
Adam C; King S; Allgeier T; Braumüller H; Lüking C; Mysliwietz J; Kriegeskorte A; Busch DH; Röcken M; Mocikat R
Blood; 2005 Jul; 106(1):338-44. PubMed ID: 15769894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
